WO2012078793A3 - Methods and compositions related to tazarotene-induced gene 1 (tig1) - Google Patents

Methods and compositions related to tazarotene-induced gene 1 (tig1) Download PDF

Info

Publication number
WO2012078793A3
WO2012078793A3 PCT/US2011/063798 US2011063798W WO2012078793A3 WO 2012078793 A3 WO2012078793 A3 WO 2012078793A3 US 2011063798 W US2011063798 W US 2011063798W WO 2012078793 A3 WO2012078793 A3 WO 2012078793A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
tig1
tazarotene
induced gene
compositions related
Prior art date
Application number
PCT/US2011/063798
Other languages
French (fr)
Other versions
WO2012078793A2 (en
Inventor
Naoto I. Ueno
Xiaoping Wang
Lajos Pusztai
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Publication of WO2012078793A2 publication Critical patent/WO2012078793A2/en
Publication of WO2012078793A3 publication Critical patent/WO2012078793A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Certain embodiments of the invention are directed to the measurement of TIGl levels in a tumor and characterization of the tumor. For example, elevated TIGl levels can be used to determine the aggressiveness of a cancer, such as to determine if a patient has inflammatory breast cancer. Methods for treating cancer by inhibiting TIGl activity are also provided.
PCT/US2011/063798 2010-12-07 2011-12-07 Methods and compositions related to tazarotene-induced gene 1 (tig1) WO2012078793A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42067010P 2010-12-07 2010-12-07
US61/420,670 2010-12-07

Publications (2)

Publication Number Publication Date
WO2012078793A2 WO2012078793A2 (en) 2012-06-14
WO2012078793A3 true WO2012078793A3 (en) 2012-11-01

Family

ID=46207722

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/063798 WO2012078793A2 (en) 2010-12-07 2011-12-07 Methods and compositions related to tazarotene-induced gene 1 (tig1)

Country Status (1)

Country Link
WO (1) WO2012078793A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018010485A (en) * 2016-03-04 2019-01-10 Jn Biosciences Llc Antibodies to tigit.
MX2022015157A (en) 2020-06-02 2023-01-16 Arcus Biosciences Inc Antibodies to tigit.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090275021A1 (en) * 2005-11-27 2009-11-05 Osnat Sella-Tavor Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090275021A1 (en) * 2005-11-27 2009-11-05 Osnat Sella-Tavor Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JING, C. ET AL.: "TAZAROTENE-INDUCED GENE 1(TIG1) EXPRESSTION IN PROSTATE CA RCINOMAS AND ITS RELATIONSHIP TO TUMORIGENICITY", JOURNAL OF THE NATIONAL CANCE R INSTITUTE, vol. 94, no. 7, 3 April 2002 (2002-04-03), pages 482 - 490 *
WANG, X. ET AL.: "TAZAROTENE-INDUCED GENE1(TIG1) IS A NOVEL TUMORIGENIC GENE OF INFLAMMATORY BREAST CANCER", CANCER RESEARCH, vol. 70, no. 24 , S, 15 December 2010 (2010-12-15) *
YOUSSEF, E, M. ET AL.: "HYPERMETHYLATION AND SILENCING OF THE PUTATIVE TUMOR SUPPRESSOR TAZAROTENEOINDUCED GENE 1 IN HUMAN CANCERS", CANCER RESEARCH, vol. 64, no. 7, 1 April 2004 (2004-04-01), pages 2411 - 2417 *

Also Published As

Publication number Publication date
WO2012078793A2 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
PH12020500203A1 (en) Identification of lkb1 mutation as a predictive boimarker for sensitivity to tor kinase inhibitors
PH12015502575B1 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
MX2013004491A (en) Boronates as arginase inhibitors.
WO2012068383A3 (en) ncRNA AND USES THEREOF
WO2012104007A3 (en) 7-azaindole derivatives
MX2014013090A (en) Pyrrolotriazinone derivatives.
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
MX2015007205A (en) Histone demethylase inhibitors.
MX2019000225A (en) Compositions and methods for treatment of autoimmune and other disease.
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
WO2014031859A3 (en) Compositions and methods relating to blood-based biomarkers of breast cancer
MX362939B (en) (aza-)isoquinolinone derivatives.
MX339709B (en) Wnt antagonists and methods of treatment and screening.
WO2010031825A3 (en) Methods and compositions for the treatment of cancer
WO2013023084A3 (en) Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
SG10201810928SA (en) Novel antitumoral use of cabazitaxel
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
MX2012006822A (en) 1, 7 - diazacarbazoles and their use in the treatment of cancer.
MX2013002155A (en) Compounds for treatment of cancer.
WO2010101793A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
WO2011143344A3 (en) Use of brown midrib-3 gene specific markers in maize for trait introgression

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11847375

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11847375

Country of ref document: EP

Kind code of ref document: A2